Elsevier

Kidney International

Volume 87, Issue 1, January 2015, Pages 62-73
Kidney International

Review
The definition of acute kidney injury and its use in practice

https://doi.org/10.1038/ki.2014.328Get rights and content
Under an Elsevier user license
open archive

Acute kidney injury (AKI) is a common syndrome that is independently associated with increased mortality. A standardized definition is important to facilitate clinical care and research. The definition of AKI has evolved rapidly since 2004, with the introduction of the Risk, Injury, Failure, Loss, and End-stage renal disease (RIFLE), AKI Network (AKIN), and Kidney Disease Improving Global Outcomes (KDIGO) classifications. RIFLE was modified for pediatric use (pRIFLE). They were developed using both evidence and consensus. Small rises in serum creatinine are independently associated with increased mortality, and hence are incorporated into the current definition of AKI. The recent definition from the international KDIGO guideline merged RIFLE and AKIN. Systematic review has found that these definitions do not differ significantly in their performance. Health-care staff caring for children or adults should use standard criteria for AKI, such as the pRIFLE or KDIGO definitions, respectively.

These efforts to standardize AKI definition are a substantial advance, although areas of uncertainty remain. The new definitions have enabled the use of electronic alerts to warn clinicians of possible AKI. Novel biomarkers may further refine the definition of AKI, but their use will need to produce tangible improvements in outcomes and cost effectiveness. Further developments in AKI definitions should be informed by research into their practical application across health-care providers. This review will discuss the definition of AKI and its use in practice for clinicians and laboratory scientists.

KEYWORDS

acute kidney injury
creatinine
chronic kidney disease

Cited by (0)

The views expressed in this publication are those of the authors and not necessarily those of the Institute. Dr Ostermann has received speaker honoraria from Fresenius, Gilead, and Alere and has taken part in educational meetings sponsored by Fresenius. All the other authors declared no competing interests.